These pieces of evidence demonstrate that the protective effects of EGCG against obesity induced inflammation and metabolic disorders are dose-response phenomena by controlling the acetylation state via the inhibition of HAT activity. The gene discussed is TMPRSS11D; the disease is Obesity.